Chest
EditorialsShould We “Rescue” Patients With 2009 Influenza A(H1N1) and Lung Injury From Conventional Mechanical Ventilation?
References (0)
Cited by (40)
Commentary: COVID-19 extracorporeal membrane oxygenation: A long way from home
2022, Journal of Thoracic and Cardiovascular SurgeryExtracorporeal membrane oxygenation-hemostatic complications
2015, Transfusion Medicine ReviewsExtracorporeal membrane oxygenation in adults for severe acute respiratory failure
2014, Annales Francaises d'Anesthesie et de ReanimationCitation Excerpt :The absolute risk of a plateau pressure > 30–32 cmH2O, compared to all the risk factors associated with ECMO, remains unknown. Similarly, we do not know how to balance the risk of injury from over-distension of the lungs versus the risk of lung under-recruitment in patients with severe hypoxemic ARDS [21]. Indeed, once the patients are on ECMO, tidal volume is significantly reduced by almost half [22], which leads to significant reduction in plateau pressure [7] and derecruitment as PEEP remains stable [23].
A conceptual approach to improving care in pandemics and beyond: Severe lung injury centers
2013, Journal of Critical CareCitation Excerpt :The standard treatment of ARDS is lung protective ventilation, a ventilator strategy that has been shown to significantly decrease mortality rates from ARDS, and a fluid restrictive strategy management, which increases ventilator-free days [7,44]. In severe cases of ARDS, lung protective ventilation may be augmented by one or more advanced modalities including prone position ventilation, inhaled nitric oxide, inhaled prostacyclin, and high-frequency oscillating ventilation [8]. These are often called “rescue” therapies because they tend to be used when standard ventilation fails to sustain normoxia.
Effectiveness of extracorporeal membrane oxygenation when conventional ventilation fails: Valuable option or vague remedy?
2012, Journal of Critical CareCitation Excerpt :The overall survival to hospital discharge based on the data from ELSO registry is 67% when ECMO was used in adults with severe respiratory failure. The increasing reports and reviews on successful use of ECMO in the 2009 H1N1 pandemic [31,36,39,40] were matched with reviews questioning the efficacy of ECMO in patients with severe respiratory failure [21,22,41]. Some argued that there is no evidence to support the use of ECMO [41].
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestpubs.org/site/misc/reprints.xhtml).